Forte Biosciences, Inc. Announces Results and Provides Clinical Update

About this update from Forte Biosciences, Inc.

[{"type":"text","content":"DALLAS, March 31, 2025--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced full year 2024 results and provides a clinical update.","length":270,"tagName":"p"},{"type":"text","content":""2024 was a very productive year with significant progress on the development of FB102, including the completion of the healthy volunteer study and the initiation of celiac patient trial," said Forte Biosciences CEO Paul Wagner, Ph.D.","length":244,"tagName":"p"},{"type":"text","content":""The celiac patient trial is progressing very well. Nearly half of the patients have completed both FB102 dosing and the gluten challenge. FB102 continues to be well-tolerated and there have been no dropouts to date. We are looking forward to reading out the topline results of the trial in the second quarter of 2025. Additionally, we are expecting to dose the first patient in the FB102 vitiligo trial shortly. 2025 is shaping up to be a very eventful year which we believe will further validate the potential for FB102."","length":533,"tagName":"p"},{"type":"text","content":"2024 Operating Results","length":22,"tagName":"p"},{"type":"text","content":"Research and development expenses were $21.2 million for the year ended December 31, 2024, compared to $21.9 million during the same period in 2023. The decrease of $0.7 million was primarily due to a decrease of $7.0 million in manufacturing expenses primarily offset by increases of $5.5 million in preclinical and clinical expenses as our FB102 program entered the clinic, and a net increase in payroll and related expenses of $1.3 million primarily due to an increase in headcount.","length":485,"tagName":"p"},{"type":"text","content":"General and administrative expenses were $15.4 million for the year ended December 31, 2024 compared to $10.6 million for the same period in 2023. The increase of $4.8 million was primarily due to an increase in professional and legal expenses.","length":244,"tagName":"p"},{"type":"text","content":"Net losses per share were $(12.17) and $(24.92) for the years ended December 31, 2024 and 2023, respectively.","length":109,"tagName":"p"},{"type":"text","content":"Forte ended 2024 with $58.4 million in cash, cash equivalents and short-...

More updates from Forte Biosciences, Inc.